Ger­man drug­mak­er files $21.6M IPO for skin can­cer drug

Ger­man biotech Biofron­tera is look­ing to raise $21.6 mil­lion in a US IPO to fund de­vel­op­ment and mar­ket­ing of its late-stage skin care drug.

The com­pa­ny is the mak­er of Ameluz (amino­lae­vulin­ic acid), ap­proved by the FDA in com­bi­na­tion with a med­ical de­vice for the skin can­cer pre­cur­sor ac­tinic ker­ato­sis. Now, Biofron­tera aims to ex­pand its la­bel so it can be used in su­per­fi­cial basal cell car­ci­no­ma, a form of squa­mous cell car­ci­no­ma called Bowen’s dis­ease, and larg­er treat­ment ar­eas of ac­tinic ker­ato­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER